Exploring the "iron shuttle" hypothesis in chelation therapy: Effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture

Journal of Laboratory and Clinical Medicine

Volumn 138, Issue 2, 2001, Pages 130-138

  Link, Gabriela ^a   Konijn, Abraham M ^a   Breuer, William ^a   Cabantchik, Z Ioav ^a   Hershko, Chaim ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0034928342     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1067/mlc.2001.116487     Document Type: Article

References (42)

1. Results of long-term iron chelating therapy
2. Survival of medically treated patients with homozygous β-thalassemia
3. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheteters in high-risk β-thalassemia
4. Iron chelators for thalassaemia
5. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
6. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients
7. Results of long-term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators
8. Iron chelation: Rationale for combination therapy
9. Biologic models for studying iron chelating drugs
10. Heart cells in culture: A model of myocardial iron overload and chelation
11. Phenolic ethylenediamine derivatives: A study of orally effective iron chelators
12. Storage iron kinetics III: Study of desferrioxamine action by selective radioiron labels of RE and parenchymal cells
13. Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: Studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores
14. IRC11, a new synthetic chelator with selective interaction with catabolic red blood iron. Evaluation in hypertransfused rats and in iron-loaded rat heart in culture
15. Sex difference in the ferritin content of rat liver
16. A simple technique for measuring storage iron concentrations in formalinized liver samples
17. Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: Studies in rat heart cells in culture
18. Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility
19. Role of iron in the potentiation of anthracycline cardiotoxicity: Identification of heart cell mitochondria as a major site of iron-anthracycline interaction
20. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells
21. Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: Mitochondrial function in cultured, iron-loaded heart cells
22. Heart cells in culture: A simple method for increasing the proportion of myoblasts
23. Desferrioxamin-chelatable iron (DCI), a component of serum non-transferrin iron (NTBI) used for assessing iron chelation therapy
24. Iron-chelation therapy with oral deferiprone in patients with thalassemia major
25. Safety profile of the oral iron chelator deferiprone: A multicentre study
26. Absence of deferiprone-induced hepatic fibrosis: A multi-center study
27. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1)
28. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients
29. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload
30. The pharmacokinetics and pharmacodynamics of the oral chelator deferiprone (L1) in relation to hemoglobin levels
31. Evidence of toxicity due to 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in normal rats
32. Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyrid-4-one, CP94, relates to differing metabolism of the iron chelating site
33. Iron chelator chemistry
34. Combined therapy with deferiprone and desferrioxamine
35. Deferiprone: How to make it work more widely, effectively and without adverse effect: An Indian study
36. Oral iron chelation: A potential role for HBED in combination therapy
37. Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease
38. The identification of 2,3-dihydroxybenzoic acid as a potentially useful iron-chelating drug
39. Annotation: Oral iron chelation therapy for thalassaemia: An uncertain scene
40. Synthesis, physicochemical properties and biological evaluation of aromatic ester pro-drugs of 1-(2′-hydroxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP 102): Orally active iron chelators with clinical potential
41. Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease
42. ICL670A: A new synthetic oral chelator: Evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture